orexigen therapeutics inc
(OREX:NASDAQ GS)
Earnings & Estimates Summary - OREXIGEN THERAPEUTICS INC (OREX)
2012 revenues at Orexigen Therapeutics, Inc. totaled $3.4M USD, while annual losses equaled $1.27 per share.
Quarterly Earnings & Estimates - OREXIGEN THERAPEUTICS INC (OREX)
40.00%
Orexigen Therapeutics, Inc.'s Quarterly Earnings
Orexigen Therapeutics, Inc. reported 1st quarter 2013 losses of $0.21 per share on 05/10/2013.
Annual Earnings & Estimates - OREXIGEN THERAPEUTICS INC (OREX)
Orexigen Therapeutics, Inc.'s Annual Earnings
Orexigen Therapeutics, Inc. reported annual 2012 losses of $1.27 per share on 03/15/2013.
Quarterly Revenues - OREXIGEN THERAPEUTICS INC (OREX)
Orexigen Therapeutics, Inc.'s Quarterly Revenues
Orexigen Therapeutics, Inc. had 1st quarter 2013 revenues of $857.0K USD. This missed the $891.4K USD consensus estimate of the 8 analysts following the company. This was the same as the prior year's 1st quarter results.
Annual Revenues - OREXIGEN THERAPEUTICS INC (OREX)
Orexigen Therapeutics, Inc.'s Annual Revenues
Orexigen Therapeutics, Inc. had revenues for the full year 2012 of $3.4M USD. This was -22.1% below the prior year's results.
| Recently Viewed | |||
| OREX:US | $6.33 USD | -0.05 |  |
| Company | Last | Change |
| Enzon Pharmaceuticals Inc | $1.70 USD | 0.00 |
| NeurogesX Inc | $0.01 USD | -0.0009 |
| Optimer Pharmaceuticals Inc | $14.33 USD | -0.11 |
| Synta Pharmaceuticals Corp | $3.88 USD | -0.12 |
| View Industry Companies | ||
Industry Analysis
OREX
Industry Average
| Valuation | OREX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 168.1x |
|
| Price/Book | 10.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 142.7x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact OREXIGEN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
